# A Perfect Storm & A Perfect Opportunity:

The Story of an Innovative HCV/HIV Screening and LTC Program for Substance Users in Georgia, USA

#### Authors

Sutton, M<sub>1</sub>, Holloway W<sub>2</sub>, McCorkle A<sub>3</sub>, Loudermilk J<sub>4</sub>, Imagine Hope<sub>1</sub>, The Athens Clinic<sub>2</sub>. The Pittard Clinic

Publication Date: September 11, 2019

## **Addressing the Impact of the American Opioid Epidemic**



Next to track marks, Katie H. wears a tattoo which represents her goal to break free from drugs. Photo: NY Times

### **Model of Care**

- Building HCV services on top of existing robust HIV screening programs in traditional and medication assisted treatment programs (MAT)
- 3 dedicated linkage coordinators statewide working to navigate options for care for a mostly uninsured population
- Building capacity for treating HCV in-house at 4 MAT clinics

**Number of Partner Agencies** 

2015 2016 2017 2018 2019 10 20 24 31 35

## **Efforts & Effectiveness**

30,939 patients screened

3,194 of those tested were HCV Ab+

CV Ab+ for RNA

10.3% 98%

3,133 2,226 confirmed for RNA RNA+

**7.2%**MATS alone 9%

1,129 of RNA+ patients educated

50.7%

639 of RNA+ patients linked to care

28.7%

Since April 2015 **30,939** patients were screened for HCV at **31** clinics in Georgia, **14** of which are MAT (data 4/1/2015 - 3/30/2019)

## Conclusion

- Routine HCV screening is feasible, replicable, and scalable
- Embedding HCV treatment in medication assisted treatment programs is effective in removing multiple barriers to care
- Followed 151 clients who have obtained Viral Load Suppresion, 17 currently on treatment



Imagine Hope receives funding from the Georgia Department of Behavioral Health and Developmental Disabilities and Gilead Sciences FOCUS project.



www.ImagineHope.com marie@imaginehope.com Phone: 404.606.1728 227 Sandy Springs PI • Suite 379-D, Atlanta, GA 30328

Gilead Sciences FOCUS program limits its support to testing and linkage to care. FOCUS does not support treatment and remains agnostic partners'in treatment decisions.